SUBSCRIBE
SUBSCRIBE
News   Policy

U.S. FDA Panel Rejects FDA and Genentech (South SF)'s (JOBS) Xolair Asthma Drug for Children

November 19, 2009 | 
1 min read
Bookmark and Share

Reuters -- Roche and Novartis's asthma drug Xolair should not be approved for children aged 6 to 11, a U.S. advisory panel decided on Wednesday.
Regulatory
Genentech, Inc. Food and Drug Administration (FDA)
MORE ON THIS TOPIC
Digital compass. Business strategic explorer, Vision crisis, Mission path, Agency creative, Digital strategy, Market decision, Achievement strategy, Financial stock, Company vision concepts
Policy
FDA Policy Tracker 2026: RMAT Awards for Assets on Hold, Animal Testing Alternatives
March 19, 2026
 · 
9 min read
 · 
BioSpace Editorial Staff
Editable vector illustration of a man winning a race. Hi-res jpeg file included.
Approvals
J&J Wins FDA Nod for First Targeted Oral Anti-IL-23 Therapy for Plaque Psoriasis
March 18, 2026
 · 
2 min read
 · 
Tristan Manalac
Podcast
Kennedy’s Vaccine Agenda Stalled, Structure’s ‘Competitive’ Obesity Pill, Novo’s Warning Letter
March 18, 2026
 · 
1 min read
 · 
Heather McKenzie
IN PARTNERSHIP WITH DIA
Webinar: Operationalizing AI in Drug Development: Inside DIA’s Global AI Consortium
March 17, 2026
 · 
1 min read
 · 
BioSpace Insights